Oncoinvent ASA (BRRGF)
0.025
0.00 (0.00%)
USD |
OTCM |
Jun 08, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 0.0152M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -99.00% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | 0.0169 |
| Price to Book Value | 0.0014 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -- |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 100.00% |
Profile
| Oncoinvent ASA operates as a clinical-phase biotechnology company, which engages in the development of radiopharmaceutical treatment products for cancer therapy. Its focus product is Radspherin, which uses the alpha-emitting radionuclide radium-224 that targets residual micrometastases after surgery in the abdominal cavity. The company was founded by Roy H. Larsen, Øyvind Bruland, Dr. Tina Bønsdorff, and Dr. Thora Jonasdottir on December 21, 2007 and is headquartered in Oslo, Norway. |
| URL | http://www.oncoinvent.com |
| Investor Relations URL | N/A |
| HQ State/Province | Oslo |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Aug. 27, 2026 |
| Last Earnings Release | Feb. 26, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Oncoinvent ASA operates as a clinical-phase biotechnology company, which engages in the development of radiopharmaceutical treatment products for cancer therapy. Its focus product is Radspherin, which uses the alpha-emitting radionuclide radium-224 that targets residual micrometastases after surgery in the abdominal cavity. The company was founded by Roy H. Larsen, Øyvind Bruland, Dr. Tina Bønsdorff, and Dr. Thora Jonasdottir on December 21, 2007 and is headquartered in Oslo, Norway. |
| URL | http://www.oncoinvent.com |
| Investor Relations URL | N/A |
| HQ State/Province | Oslo |
| Sector | Health Care |
| Industry | Pharmaceuticals |
| Next Earnings Release | Aug. 27, 2026 |
| Last Earnings Release | Feb. 26, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |